The JCPYV DNA load inversely correlates with the viral microrna expression in blood and cerebrospinal fluid of patients at risk of PML

Rocca, Arianna; Martelli, Francesco; Delbue, Serena; Ferrante, Pasquale; Bartolozzi, Dario; Azzi, Alberta; Giannecchini, Simone

doi:10.1016/j.jcv.2015.06.104

Cited by 23 publications

(39 citation statements)

References 24 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The expressions of JCPyV 5p and 3p were reported in 2 out of 4 (50%) PBMCs of MS patients, in 12 and 5 out of 17 (70% and 29%, respectively) PBMCs of MS patients during treatment with natalizumab, and in 1 out of 2 (50%) PBMCs from healthy subjects . JCPyV miRNA 5p and 3p expressions in HIV positive patients were observed in 21 and 9 out of 100 (21% and 9%, respectively) PBMCs examined . Of note, miRNA expression in PBMCs of MS patients, with or without natalizumab therapy, and of healthy subjects was higher than that in PBMCs of HIV patients (range of expression of 520‐1600 copies/ng of total RNA versus 65‐160 copies/ng of total RNA for MS and healthy subjects versus HIV patients, respectively) .…”

Section: Introductionmentioning

confidence: 90%

“…Additional investigations were conducted to check the presence of JCPyV miRNAs expression in subjects with low and high risks for PML. In particular, the expression of JCPyV miRNA was investigated in peripheral blood mononuclear cells (PBMC) obtained from multiple sclerosis (MS) patients before and during natalizumab treatment, HIV‐infected patients, and healthy subjects . The expressions of JCPyV 5p and 3p were reported in 2 out of 4 (50%) PBMCs of MS patients, in 12 and 5 out of 17 (70% and 29%, respectively) PBMCs of MS patients during treatment with natalizumab, and in 1 out of 2 (50%) PBMCs from healthy subjects .…”

Section: Introductionmentioning

confidence: 99%

“…In human Merkel cell carcinoma tumors, MCPyV miRNA 5p was expressed at low levels in 50% of MCPyV‐positive Merkel cell carcinomas . Several groups have examined polyomavirus miRNAs circulating in biological fluids obtained from subjects with different polyomaviruses DNA prevalence (Table ) . The first and second studies involved the same MS and HIV patients and healthy controls included in the study of the PBMC polyomavirus miRNA expression, reported above .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Polyomavirus microRNAs circulating in biological fluids during viral persistence

Martelli

Giannecchini

2017

Reviews in Medical Virology

Self Cite

View full text Add to dashboard Cite

Increasing evidence suggests that microRNA-mediated gene silencing, detected during exosome intercellular communication between cells, may be exploited by persistent human viruses. Recently, it has been reported that human polyomaviruses encode microRNAs that downregulate large T expression and target host factors, helping the virus to escape immune elimination. Consequently, viral microRNAs and their genetic variability may have roles in the induction of polyomavirus reactivation, the success of persistence or replication and the development of diseases. In vitro experiments have detected polyomavirus JC (JCPyV) microRNAs in exosomes obtained from cell supernatants after viral infection and showed that they can be carried into uninfected cells. JCPyV and BKPyV microRNAs have been sought in clinical samples obtained from patients with or at risk of severe polyomavirus-associated diseases and from healthy subjects. Variable expressions of JCPyV and BKPyV microRNAs circulating in blood, urine, and cerebrospinal fluid samples were found in patients who were polyomavirus DNA positive and were also observed in negative subjects. Differences in the relationship between the JCPyV and BKPyV microRNA expressions and viral DNA load have been observed. All the data point towards a potential role of polyomavirus exosome microRNAs in viral persistence and suggest that further work is warranted to define their role in viral reactivation and to identify potential new antiviral strategies targeting these viruses.

show abstract

Section: Introductionmentioning

confidence: 90%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Polyomavirus microRNAs circulating in biological fluids during viral persistence

Martelli

Giannecchini

2017

Reviews in Medical Virology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Thus, these data indicate that analysis of circulating viral miRNAs divulged the presence of latent JCV infection. Rocca et al investigated the presence of JCV DNA and expression of JCV miRNA in clinical specimens from patients at risk for PML and found that JCV viral load was inversely correlated with the levels of JCV miRNA expression in blood and cerebrospinal fluid of patients at risk of PML indicating a potential clinical relevance for JCV miRNA in PML risk assessment. The field of viral miRNA is a fairly new one, and it is probable that exciting new advances will be made in the future.…”

Section: Tests Involving Minimally Invasive Assaysmentioning

confidence: 99%

Diagnostic assays for polyomavirus JC and progressive multifocal leukoencephalopathy

White

Sariyer

Gordon

et al. 2015

Reviews in Medical Virology

Self Cite

View full text Add to dashboard Cite

SUMMARY Progressive multifocal leukoencephalopathy (PML) is a devastating and often fatal demyelinating disease of the central nervous system (CNS) for which effective therapies are lacking. It is caused by the replication of polyomavirus JC (JCV) in the oligodendrocytes and astrocytes leading to their cytolytic death and loss of myelin from the subcortical white matter. While the virus is very common in human populations worldwide, the incidence of the disease is very low and confined almost exclusively to individuals with some form of immunological dysfunction. However, the number of people who constitute the at-risk population is growing larger and includes individuals with HIV-1/AIDS and patients receiving immunomodulatory therapies such as multiple sclerosis patients treated with natalizumab. Further adding to the public health significance of this disease are the difficulties encountered in the diagnosis of PML and the lack of useful biomarkers for PML progression. In this review, we examine the diagnostic assays that are available for different aspects of the JCV life cycle, their usefulness and drawbacks, and the prospects for improvements.

show abstract

“…Unlike the other human PyV, BKPyV and JCPyV encode an accessory protein in the late region, referred to as the agnoprotein [16]. In addition, viral encoded miRNAs, which have the ability to negatively regulate the expression of viral gene expression, have been found to be encoded by BKPyV, JCPyV and MCPyV [31,32,33,34]. …”

Section: The Pyv Life Cyclementioning

confidence: 99%

In Vitro and In Vivo Models for the Study of Human Polyomavirus Infection

Barth

Solis

Kack-Kack

et al. 2016

Viruses

View full text Add to dashboard Cite

Developments of genome amplification techniques have rapidly expanded the family of human polyomaviruses (PyV). Following infection early in life, PyV persist in their hosts and are generally of no clinical consequence. High-level replication of PyV can occur in patients under immunosuppressive or immunomodulatory therapy and causes severe clinical entities, such as progressive multifocal leukoencephalopathy, polyomavirus-associated nephropathy or Merkel cell carcinoma. The characterization of known and newly-discovered human PyV, their relationship to human health, and the mechanisms underlying pathogenesis remain to be elucidated. Here, we summarize the most widely-used in vitro and in vivo models to study the PyV-host interaction, pathogenesis and anti-viral drug screening. We discuss the strengths and limitations of the different models and the lessons learned.

show abstract

The JCPYV DNA load inversely correlates with the viral microrna expression in blood and cerebrospinal fluid of patients at risk of PML

Cited by 23 publications

References 24 publications

Polyomavirus microRNAs circulating in biological fluids during viral persistence

Polyomavirus microRNAs circulating in biological fluids during viral persistence

Diagnostic assays for polyomavirus JC and progressive multifocal leukoencephalopathy

In Vitro and In Vivo Models for the Study of Human Polyomavirus Infection

Contact Info

Product

Resources

About